In sleep-related clinical drug development, understanding the relationship between cognition, sedation, and wakefulness is crucial to making decisions about the safety and efficacy of new medicines. As researchers and sponsors increasingly focus on optimizing wakefulness and managing sleepiness, cognitive assessment is becoming an important marker of central nervous system function.
In this paper, Professor Paul Maruff, Chief Innovation Officer at Cogstate, explores some insights and methodologies that can help clinical trial teams improve decision-making in this area.
Please fill out the form below to download the whitepaper and learn more.
